ABT-299

• Description :

  ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite.

• UNSPSC :

  12352005

• Target :

  Platelet-activating Factor Receptor (PAFR)

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/abt-299.html

• Smiles :

  CC(OC[N+]1=CC=CC([C@H]2SCC3=C(C=CN23)C(C4=CN(C5=C4C=CC(C6=CC=C(C=C6)F)=C5)C(N(C)C)=O)=O)=C1)=O.[Cl-]

• Molecular Formula :

  C32H28ClFN4O4S

• Molecular Weight :

  619.11

• References & Citations :

  [1]Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist|[2]Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [161395-35-3]